RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer
10 Mar, 2021 | 08:18h | UTCSecondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm https://t.co/cFq41Ck9EW pic.twitter.com/5gFsIGLBDA
— The Lancet Oncology (@TheLancetOncol) March 9, 2021